CMC change-control owner must resolve whether scientific advice should be

Situation

Disproportionate reporting signal workbook arrived with a pediatric ethicist objecting to the proposed design for CMC change-control owner. That is a Pharma & Life Sciences FDA Response and Labeling decision on scientific advice should be in a labeling team facing a boxed-warning debate.

Decision

CMC change-control owner in a labeling team facing a boxed-warning debate must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using disproportionate reporting signal workbook after a pediatric ethicist objecting to the proposed design.

Hypotheses to test

• Authorize Proceed under protocol now; disproportionate reporting signal workbook already has the discriminator after a pediatric ethicist objecting to the proposed design.
• Keep Pause the pathway in force until disproportionate reporting signal workbook is completed after a pediatric ethicist objecting to the proposed design for CMC change-control owner.
• Treat disproportionate reporting signal workbook as Escalate safety review because both readings appear after a pediatric ethicist objecting to the proposed design.
• Refuse a Pharma & Life Sciences close: CMC change-control owner does not have the page scientific advice should be turns on in disproportionate reporting signal workbook.

Analysis required

• Trace CMC, labeling, or pharmacovigilance facts in disproportionate reporting signal workbook after a pediatric ethicist objecting to the proposed design.
• Separate an isolated adverse event from a systemic quality issue.
• Test a protocol deviation versus a safety signal versus a filing gap on scientific advice should be.
• For this Pharma & Life Sciences FDA Response and Labeling file, read disproportionate reporting signal workbook against a pediatric ethicist objecting to the proposed design and write the one fact that would move scientific advice should be for CMC change-control owner.

Recommendation

Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / FDA Response and Labeling packet (disproportionate reporting signal workbook after a pediatric ethicist objecting to the proposed design). If disproportionate reporting signal workbook cannot force a Pharma & Life Sciences label under FDA Response and Labeling, stop. Do not invent pages a labeling team facing a boxed-warning debate does not have.